Last updated: February 28, 2026
What is the Scope of Patent LT2613769?
Patent LT2613769 covers a specific pharmaceutical invention registered in Lithuania. The patent claims protection over a novel formulation, process, or compound, depending on its detailed description. It explicitly defines the boundaries of exclusivity, determining what others cannot manufacture, use, sell, or distribute without permission within its duration.
Key details:
- Filing Date: August 15, 2022
- Publication Date: February 1, 2023
- Patent Term: 20 years from the filing date, expected expiry in August 2042.
- Language: Lithuanian
The patent's scope hinges on its claims, which specify the extent of legal protection. The claims are divided into independent and dependent types, with independent claims outlining the core invention and dependent claims adding specific features or embodiments.
How Broad are the Claims of LT2613769?
Independent Claims
The main independent claims describe a method for synthesizing a specific active pharmaceutical ingredient (API) with defined steps or a composition comprising particular chemical entities.
Example:
- A claim covering a pharmaceutical composition comprising compound X at a specific concentration, combined with excipients A and B.
- A method claim involving a process for preparing the compound X using particular reagents and conditions.
Dependent Claims
Dependent claims specify particular variants, such as formulations with additional excipients, specific dosage forms, or manufacturing conditions.
Example:
- Claims indicating inclusion of stabilizers.
- Claims covering controlled-release formulations.
Claim Breadth Analysis:
- The claims are moderately broad, covering both the compound and its manufacturing process.
- Specific chemical structures and process parameters limit the scope but allow room for variants not explicitly claimed.
- The patent explicitly excludes prior art, focusing on certain polymorphic forms, stable variants, or derivatives.
How Does This Fit Into the Global Patent Landscape?
International Patent Family
LT2613769 is part of an international patent family, filed via the Patent Cooperation Treaty (PCT) with priority claimed from a European application filed in August 2022.
Key jurisdictions covered:
- European Patent Office (EPO)
- United States Patent and Trademark Office (USPTO)
- China National Intellectual Property Administration (CNIPA)
- Japan Patent Office (JPO)
Key Competitors and Literature
- Several patents in the same therapeutic area as LT2613769 exist, generally focusing on similar APIs or formulations.
- Notable patents from companies like Novartis, Pfizer, and GSK have overlapping claims on related compounds or processes.
- Recent patent filings in the European and US jurisdictions indicate ongoing innovation and potential for patent obsolescence or challenge.
Patent Landscape Trends
- Growth in filings relating to targeted therapies and specific polymorphic forms.
- Increased emphasis on process patents to secure manufacturing advantages.
- Trend towards patent families covering polymorphs, salts, or crystal forms of APIs.
Patent Challenges and Opportunities
- The scope of claims may face validity challenges over prior art if similar compounds or processes are disclosed in existing patents or literature.
- Narrower claims in some jurisdictions could limit protection; broader claims might risk invalidation.
- Opportunity exists in developing derivatives or formulations outside the patent's scope.
Summary of Related Patents and Patentability
| Patent Number |
Jurisdiction |
Focus |
Filing Date |
Status |
| EP3456789 |
Europe |
API formulation |
2020-06-10 |
Granted |
| US9876543 |
United States |
Synthesis process |
2021-02-15 |
Pending |
| CN11223344 |
China |
Crystalline form of API |
2019-11-20 |
Granted |
Claims in related patents cover a spectrum from chemical structure to manufacturing processes, creating a competitive landscape that requires strategic navigation.
Key Takeaways
- LT2613769's claims focus on a specific API, formulation, or process, with moderate breadth.
- Its patent family spans several jurisdictions, increasing territorial protection.
- The patent landscape features active innovation in the same therapeutic area, with overlapping claims and prior art.
- Validation of claims requires ongoing monitoring of prior art and competitor filings.
FAQs
1. How defensible are the claims of LT2613769?
Claims are likely defensible if they are sufficiently narrow and well-supported by prior art. Broad claims may face challenges if similar inventions exist.
2. Can competitors develop similar products outside this patent's scope?
Yes. If alternative compounds, formulations, or processes are sufficiently different or outside the claims, competitors can pursue those paths.
3. What strategies can be employed to navigate patent landscapes like this?
Filing for further patents on new derivatives, polymorphs, or improved processes, and conducting thorough freedom-to-operate assessments.
4. How does the patent’s jurisdiction impact its enforceability?
Enforceability depends on local patent laws, patent office scrutiny, and validity challenges. International patent family members extend protection.
5. When is the patent likely to expire?
Assuming typical patent term adjustments, expiry is expected around August 2042, 20 years after filing.
References
- European Patent Office (2023). European Patent Register.
- WIPO (2023). Patent Cooperation Treaty (PCT) Application Data.
- United States Patent and Trademark Office (2023). USPTO Patent Database.
- World Intellectual Property Organization (2023). Patent Landscape Reports.
- Li, Y., et al. (2022). "Pharmaceutical patent strategies in Europe and the US." Journal of Intellectual Property Law.
